Opinion

Video

Considerations for Choosing Advanced Treatments and Setting Patient Expectations

Author(s):

Silvio Danese, MD, PhD ,Bruce Sands, MD

Gastroenterologist experts discuss the current landscape of biologic treatments for inflammatory bowel disease and the occasional necessity to switch between different biologic agents, while also sharing insights on their preferred treatment sequencing strategies.

  1. When do you consider starting or switching advanced treatment for UC and CD?
  2. How do you communicate with the patient about starting an advanced treatment?
Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Related Content
US FDA logo in black over a white background. | Credit: US Food and Drug Administration
November 23rd 2024

FDA Approves Acoramidis (Attruby) for ATTR-CM

Patrick Campbell
Medical Ethics Unpacked: Ethical Considerations for Euthanasia and Medically-Assisted Suicide
November 22nd 2024

Medical Ethics Unpacked: Ethical Considerations for Euthanasia & Medical Assistance in Dying

Steven Levine, MD Dominic Sisti, PhD
Protein and Glycine in Allergens: Negative Correlation with Allergy Prevalence
November 22nd 2024

Protein and Glycine in Allergens: Negative Correlation with Allergy Prevalence

Tim Smith
Medical Ethics Unpacked:
November 22nd 2024

Medical Ethics Unpacked: Ethical Foundations and Background of Euthanasia & Medically-Assisted Suicide

Steven Levine, MD Dominic Sisti, PhD
FDA Issues CRL to Avacincaptad Pegol sNDA for Geographic Atrophy | Image Credit: US Food and Drug Administration
November 22nd 2024

FDA Issues CRL to Avacincaptad Pegol sNDA for Geographic Atrophy

Connor Iapoce
Esi Lamousé-Smith, MD, PhD | Credit: Johnson & Johnson
November 22nd 2024

J&J Submits sBLA for Guselkumab (Tremfya) Subcutaneous Induction Regimen in UC

Abigail Brooks, MA
© 2024 MJH Life Sciences

All rights reserved.